Bicara Therapeutics (Nasdaq: BCAX) announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.
A live webcast will be accessible via the company’s Investor Relations website under Events and Presentations, and a replay will be archived and available after the event.
In the Dec 15 session, BCAX declined 0.65%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement highlights BCAX’s upcoming presentation at the J.P. Morgan 2026 Healthcare Confere...
Analysis
This announcement highlights BCAX’s upcoming presentation at the J.P. Morgan 2026 Healthcare Conference, giving management a venue to showcase clinical progress and capital plans. Recent history includes Breakthrough Therapy Designation, strong Phase 1/1b data, and Q3 cash of $407.6 million expected to fund operations into H1 2029. Investors may monitor use of the Form S-3 shelf, the $150,000,000 ATM program, and ongoing insider trading activity alongside future clinical and regulatory updates.
Key Figures
ATM offering size:$150,000,000S-3 shelf capacity:$400.0 millionCash & investments:$407.6 million+5 more
ATM offering size
$150,000,000
Prospectus Supplement 424B5 at-the-market equity program
Q2 results with strong Phase 1/1b data and robust cash position.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
at-the-market offering, prospectus supplement, form s-3, registration statement, +4 more
8 terms
at-the-market offeringfinancial
"is launching an at-the-market offering of up to $150,000,000 of its common stock"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
prospectus supplementregulatory
"[424B5] Bicara Therapeutics Inc. Prospectus Supplement (Debt Securities)"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
form s-3regulatory
"has filed a registration statement on Form S-3 establishing a shelf for securities"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
registration statementregulatory
"has filed a registration statement on Form S-3 establishing a shelf"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
rule 10b5-1 trading planregulatory
"The transactions were carried out under a Rule 10b5-1 trading plan adopted on"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
form 10-qregulatory
"including its Form 10-K and amendments. The prospectus discloses clinical data"
A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.
form 8-kregulatory
""[8-K] Bicara Therapeutics Inc. Reports Material Event""
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
shelfregulatory
"establishing a shelf for securities and incorporates by reference prior SEC filings"
A shelf is a pre-approved regulatory filing that lets a company register securities in advance so it can sell shares or bonds later without repeating the full approval process each time. For investors it matters because a shelf makes it quick and easy for a company to raise capital when needed — which can fund growth or pay down debt but may also dilute existing shareholders or change the company’s debt profile, similar to having a ready line of credit.
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.
A live webcast of the presentation will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. A replay of the webcast will be archived and available following the event.
About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.
